TerminatedPhase 2

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Stopped: A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

United States46 participantsStarted 2021-10-27

Plain-language summary

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Serum M-protein \>/= 0.5 g/dL by SPEP
✓. Urinary M-protein excretion \>/= 200 mg/24 hours by UPEP
✓. Serum immunoglobulin FLC \>/= 10 mg/dL (\>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio

What they're measuring

SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation

Timeframe: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 35 days)

SSB: Number of Participants With DLTs- Phase 1b

Timeframe: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 42 days)

Trial details

NCT IDNCT05090566

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-13

Results submitted2026-02-04

View on ClinicalTrials.gov More Multiple Myeloma trials